The Prolyl Hydroxylase Inhibitor BIQ/FG-2216 Stabilises HIF-1 alpha and Upregulates VEGF in vitro: A Potential Strategy For Difficult CTO Lesions in Patients.

The Prolyl Hydroxylase Inhibitor BIQ/FG-2216 Stabilises HIF-1 alpha and Upregulates VEGF in vitro: A Potential Strategy For Difficult CTO Lesions in Patients.

Xehetasun bibliografikoak
Egile Nagusiak: Barnett, G, Flashman, E, Kelly, D, Schofield, C, Gershlick, A
Formatua: Conference item
Argitaratua: 2013

Antzeko izenburuak